ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,575.90
-1.39%
S&P ASX All Technology
2,970.40
-1.25%
Brent Oil
88.165
0.00%
US Dollar vs AUD
1.53139
0.00%
Bitcoin
62,984.92
-1.18%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Altimmune Inc (ALT)

  7. Altimmune Inc (ALT) News

ALT Altimmune Inc

7.20
0.00 (0.00%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Altimmune Inc ALT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00 0.00% 7.20 08:15:55
Open Price Low Price High Price Close Price Previous Close
7.18 6.90 7.42 7.26 7.20
more quote information »

Recent News

Date Time Source Heading
26/4/202407:24GLOBEAltimmune Statement on the Passing of Dr. Stephen Harrison
27/3/202422:00GLOBEAltimmune Announces Positive Lean Mass Preservation Data for..
27/3/202421:57IHMARKETNEWSU.S. Stock Index Futures Point to a Rebound, Oil See..
20/3/202422:30GLOBEAltimmune to Report Fourth Quarter and Full Year 2023..
15/2/202404:04EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202410:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202410:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202410:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202410:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202410:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202410:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202410:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202410:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202410:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202410:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202410:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202410:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202410:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/1/202403:49EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/1/202410:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202410:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202423:30GLOBEAltimmune Announces Presentation of Pemvidutide Clinical..
09/12/202300:35GLOBEWater Tower Research US Climate Virtual Investor Conference:..
05/12/202300:35GLOBEWater Tower Research US Climate Investor Conference Agenda..
01/12/202308:28EDGAR2Form 8-K - Current report
01/12/202308:24GLOBEAltimmune Announces Positive Topline Results from MOMENTUM..
08/11/202308:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202323:06EDGAR2Form 8-K - Current report
07/11/202323:00GLOBEAltimmune Announces Third Quarter 2023 Financial Results and..
31/10/202322:30GLOBEAltimmune to Report Third Quarter 2023 Financial Results and..
26/10/202323:15DJNAltimmune Gets FDA Fast-Track Designation for Pemvidutide in..
26/10/202322:30GLOBEAltimmune Granted Fast Track Designation by FDA for..
25/10/202322:30GLOBEAltimmune to Present New Data on the Anti-Inflammatory and..
17/10/202322:30GLOBEAltimmune to Participate at Two Upcoming Investor..
30/9/202307:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/9/202307:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/9/202307:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/9/202307:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/9/202307:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202306:55EDGAR2Form 8-K - Current report
26/9/202321:30GLOBEAltimmune Announces Oral Presentation of Pemvidutide..
12/9/202321:30GLOBEAltimmune Announces Completion of Dosing in the Phase 2..
30/8/202321:30GLOBEAltimmune to Participate at Two Upcoming Investor..
17/8/202306:14EDGAR2Form ARS - Annual Report to Security Holders
17/8/202306:10EDGAR2Form DEF 14A - Other definitive proxy statements
16/8/202308:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/8/202306:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202321:04EDGAR2Form 8-K - Current report
10/8/202321:00GLOBEAltimmune Announces Second Quarter 2023 Financial Results..

Your Recent History

NASDAQ
ALT
Altimmune
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved